SCHEMBL2207669

SCHEMBL2207669

O=C(c1cc2ccccc2s1)[C@H]1CC[C@H](NCc2ccc3c(c2)OCCO3)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.44
KDM1A O60341 2/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
KDM2B Q8NHM5 1/20 0.42
LTA4H P09960 4/20 0.41
HTT P42858 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPY5R Q15761 1/20 0.40
HDAC1 Q13547 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2207677 1.00 KCNH2 (0.44) KCNH2KDM1AMAOAMAOBKDM2B
SCHEMBL2206557 0.83 PARP1 (0.48) MAOATSHR
SCHEMBL2206562 0.83 PARP1 (0.48) MAOATSHR
SCHEMBL2208550 0.83 ALDH1A1 (0.49) KCNH2KDM1AMAOAMAOBHTT
SCHEMBL2208556 0.83 ALDH1A1 (0.49) KCNH2KDM1AMAOAMAOBHTT
SCHEMBL2205345 0.78 LMNA (0.48) KCNH2MEN1KMT2AMAPTALDH1A1
SCHEMBL2205336 0.78 LMNA (0.48) KCNH2MEN1KMT2AMAPTALDH1A1
SCHEMBL5261729 0.77 LTA4H (0.57) KCNH2KDM1AMAOAMAOBLTA4H
SCHEMBL5261735 0.77 LTA4H (0.57) KCNH2KDM1AMAOAMAOBLTA4H
SCHEMBL2204313 0.77 LMNA (0.52) KCNH2MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP claimed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US claimed
US-7981886-B2 Antibiotics derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2011-07-19 US disclosed
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP disclosed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280888-A1 Antibiotics Derivatives NR4A1, NR2C2, NR4A3 KCNH2 1559/4885KDM1A 1522/4885MAOA 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.